Azurity Archives
News and events as they happenACA Pharma Named Exclusive Distributor for Ferabright™ in Macau, Hong Kong, Singapore, Greater Bay Area & Mainland China
NEW YORK, NY, UNITED STATES, January 14, 2026 — ACA Pharma and Azurity Pharmaceuticals are pleased to announce that they have entered into an exclusive distribution partnership under which ACA Pharma will commercialize FerabrightTM (ferumoxytol injection) across Macau, Hong Kong, Singapore, the Guangdong–Hong Kong–Macao Greater Bay Area (GBA) and Mainland China.
Azurity Pharmaceuticals Announces the Availability of JAVADIN™ (clonidine hydrochloride) Oral Solution
Woburn, MA—December 18, 2025—Azurity Pharmaceuticals, Inc. announced today the availability of JavadinTM (clonidine hydrochloride) oral solution, the only FDA-approved, immediate-release, ready-to-use oral liquid clonidine formulation for the treatment of hypertension in adult patients to lower blood pressure. Lowering blood pressure has been shown to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
Azurity Pharmaceuticals and Sebela Pharmaceuticals Announce the Sale of Sebela’s Bowel Prep Franchise to Azurity
Woburn, MA – November 17, 2025 – Azurity Pharmaceuticals and Sebela Pharmaceuticals announced today Azurity’s successful acquisition of Sebela’s Bowel Prep Franchise, including two leading bowel preparation therapies for colonoscopies.
Azurity Pharmaceuticals Announces FDA Approval of JAVADINTM (clonidine hydrochloride) Oral Solution
Woburn, MA—October 24, 2025—Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved JavadinTM (clonidine hydrochloride) oral solution, the only FDA-approved, immediate-release, ready-to-use oral liquid clonidine formulation for the treatment of hypertension in adult patients to lower blood pressure. Lowering blood pressure has been shown to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
